Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +24.27%
#2 MiL.k Alliance MiL.k Alliance +22.68%
#3 Biconomy Biconomy +20.40%
#4 The Black Bull The Black Bull +17.73%
#5 THORChain THORChain +17.53%
#6 Wrapped STX (Velar) Wrapped STX (Velar) +16.51%
#7 Tutorial Tutorial +13.02%
#8 THORChain Yield THORChain Yield +12.99%
#9 XPIN Network XPIN Network +12.89%
#10 MetaDAO MetaDAO +12.86%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Mirati Therapeutics, Inc. Mirati Therapeutics, Inc.

Mirati Therapeutics, Inc.

MRTX
Classifica tra le azioni #5115
Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the... Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the clinical stage, committed to identifying and developing treatments that target the genetic and immunological factors driving cancer progression. Its pipeline features MRTX849, a KRAS G12C inhibitor currently undergoing Phase 1/2 clinical trials for a range of malignancies, including non-small cell lung, colorectal, and pancreatic cancers. Additionally, the company is advancing Sitravatinib, an investigational broad-spectrum kinase inhibitor, which has reached Phase 3 clinical trials specifically for non-small cell lung cancer. Mirati also has a KRAS G12D inhibitor program in its preclinical development phase. The company has forged a collaboration and licensing agreement with BeiGene, Ltd. for the development, manufacturing, and commercialization of sitravatinib. Established in 1995, Mirati Therapeutics, Inc. maintains its headquarters in San Diego, California.
Prezzo delle azioni
$58.70
Ultima sincronizzazione: 2024-01-23
Capitalizzazione di mercato
$2.98B
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
US
Scambia Mirati Therapeutics, Inc. (MRTX)

Categoria

Healthcare
Rapporto P/B per Mirati Therapeutics, Inc. (MRTX)
Rapporto P/B al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Mirati Therapeutics, Inc., il rapporto P/B attuale (TTM) è 0. Alla fine del 2026, era pari a 0.
Storico del rapporto P/B per Mirati Therapeutics, Inc. da 2026 a 2026
Rapporto P/B alla fine di ogni anno
Anno Rapporto P/B Cambia
Non abbastanza dati per le date fornite.
Rapporto P/B per aziende simili o concorrenti
Azienda Rapporto P/B Differenza del rapporto P/B Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH